
|Articles|July 1, 2004
Fighting melanoma
New Orleans - Oblimersen sodium (Genasense), the antisense agent under investigation for advanced malignant melanoma, improved progression-free survival but not overall survival, in a recent phase III trial, Michael J. Millward, M.D. reported here at the annual meeting of the American Society of Clinical Oncology (ASCO).
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Nearly Half of Female Psoriasis Patients Report IPV, Study Finds
3
Experts See Promise in AI for Atopic Dermatitis Care
4
New Analysis Finds Radiofrequency Microneedling Superior for Rosacea Erythema and Patient Satisfaction
5


















